Vaccine Technology (COVID unwrapped) IOT and Consumer Applications

Vaccines and Consumer Technology innovation

TICKETS

https://www.eventbrite.com/e/vaccine-technology-covid-unwrapped-iot-and-consumer-applications-tickets-171573439777?aff=eand

DETAILS

Vaccine technology has made a lot of progress in the 225 years since Edward Jenner and Kathrine the Second took the inoculation practice of Turkish military doctors to public use. Lots of innovations were adopted after that time, however, the core algorithm still remains the same. The established vaccine technology just mimics the natural process:

1. The adaptive human immune system is presented with and “sees” the most prominent external part of the invading virus – so called “epitopes”. These are the viral surface proteins like the corona S-spikes on the surface of coronavirus.
2. That prompts the uniquely specific immune response (antibodies, etc). The protein against which the immune system issues its response is called an ANTIGEN. Today practically all antigens are viral epitopes. And there lies the problem.
This process is very specific to the viral epitope, and thus, the resulting immune response is uniquely specific to the given variant of the virus.
This nature-mimicking approach worked well for a long time for genetically stable DNA viruses, but has serious problems with fast-mutating RNA viruses, whose epitopes quickly mutate and render the immune response less and less effective, as proven by the current pandemic.

Since we cannot do anything to make RNA viruses less mutative, we need to abandon our nature-mimicking epitope-centered vaccine paradigm and enter the new approach in vaccine design – ANTIGEN ENGINEERING for higher vaccine universality (at least across a specific viral family).

Here we will present you the results of almost 25 years of such efforts by two different companies. We present two different, but both highly universal vaccines, both proved in-vivo and protection trials – one already in FDA trials against many adenocarcinomas, and the second, potentially opens a whole new class of viral family-specific vaccines. The last one addresses a very resistant viral family – Herpesviridae, that include many herpes viruses – from genital herpes, to Epstein-Barr, Cytomegalovirus, Kaposi’s sarcoma and more.

The event is finished.

Date

Nov 04 2021
Expired!

Time

3:00 pm - 4:00 pm

Leave A Reply

Your email address will not be published. Required fields are marked *